Oncology Pharma Reports on Progress with Ribera Solutions
Oncology Pharma Inc. (OTC PINK:ONPH) announced progress in its investment with Ribera Solutions, which has now become an independent entity named Connect2Trials, Inc.. The company is developing a patient retention platform to enhance clinical trial participation and engagement. Oncology Pharma aims to finance further development to secure significant interest in Connect2Trials. The prototype is expected by late March 2022, with pilot deployments planned for Q2 2022. Challenges such as financing and operational cash flows remain.
- Oncology Pharma's investment in Connect2Trials may provide significant interest and potential returns.
- The development of a patient retention platform addresses a critical issue in clinical trials.
- Current negative operating cash flows and a need for additional funding pose risks.
- Potential dilution of shares due to the terms of further financing.
- Uncertainties regarding customer adoption of new technologies could hinder market acceptance.
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions' Connect2Med. Ribera has segregated the business entity into a separate business unit and made it an independent entity as a Delaware Corporation under the name of Connect2Trials, Inc. Oncology Pharma's investment has been transferred to the new business and it has committed to further finance the commercial development for a significant interest in the business.
Connect2Trials, Inc. is currently developing a prototype to present and demonstrate capabilities to companies including some of the largest pharma and biotech companies in the industry. The prototype target date is scheduled for late March of 2022 subject to the availability of adequate financing. Connect2Trials is in current discussions with some of the top CRO's (Clinical Research Organizations), Advocacy Groups, and Pharma Companies for potential partnerships for pilot deployment of its MVP (Minimum Viable Product) release scheduled for 2nd quarter of this year.
For Pharmaceutical companies, CROs and sites running clinical trials, Connect2Trials offers a highly engaging patient retention platform that keeps patients motivated to complete the trial, which is currently a challenge for many trials. Connect2Trials does this through community and peer to peer interactions and incentives.
Oncology Pharma, Inc, through its investment and continuation of financing of Connect2Trials is poised to become a significant player in the trials and patient engagement space in order to increase the results of clinical trials utilizing technology and patient engagement formulas to improve the retention rate, value proposition and eventual better clinical trials in the industry.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (Connect2Trials, inc.) (www.riberasolutions.com)
Ribera Solutions (CA, USA) has developed Web based Connect2Med platform, which has been recently assigned to Connect2Trials, Inc., with iOS and Android mobile Apps. Ribera's mission is to provide solutions for solving challenging problems timely through simple, practical and economical approaches.
FORWARD-LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/691062/Oncology-Pharma-Reports-on-Progress-with-Ribera-Solutions
FAQ
What is Oncology Pharma's recent press release about?
What is Connect2Trials, Inc.?
What is the target date for the Connect2Trials prototype?
What challenges does Oncology Pharma face regarding funding?
How does Connect2Trials aim to improve clinical trials?
